FY 2024 Guidance On July 9th, the Group updated its financial guidance for FY 2024 to reflect continued near-term adverse market dynamics impacting SUBLOCADE NR growth as well as the initial commercial adoption of OPVEE and the cessation of PERSERIS sales and marketing. The guidance set out is unchanged from the July 9th guidance. At the midpoint, the Group expects solid adjusted operating profit growth of 12% and adjusted operating margin expansion of approximately 100 basis points. Guidance assumes no material change in exchange rates for key currencies compared with FY 2023 average rates, notably USD/GBP and USD/EUR. FY 2024 Net Revenue (NR) SUBLOCADE NR OPVEE NR PERSERIS NR $1,150m to $1,215m (+8% at midpoint vs. FY 2023) $765m to $805m (+25% at midpoint vs. FY 2023) $9m to $14m1 $27m to $33m SUBOXONE Film Market Share Adjusted Gross Margin Adjusted SG&A R&D Adjusted Operating Profit Assumes historic rate of share decline in FY 2024 of 1 to 2 percentage points and the potential impact from a fourth buprenorphine/naloxone sublingual film generic in the U.S. market Low to mid-80s % range ($550m) to ($560m) ($120m) to ($130m) $285m to $320m (+12% at midpoint vs. FY 2023)